Upgrade to SI Premium - Free Trial

AbbVie (ABBV)

141.59 +3.27 (2.36%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/22)
- M&A (11/30/-1 *Est)
- M&A (12/31/16 *Est)

Latest Headlines

AbbVie to Host Third-Quarter 2022 Earnings Conference Call October 4, 2022 8:00 AM - PR NewsWire AbbVie (ABBV) Ticks Off Lows September 30, 2022 12:38 PM - StreetInsider AbbVie (ABBV) Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week September 29, 2022 7:02 AM - StreetInsider AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022 September 29, 2022 7:00 AM - PR NewsWire The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery September 22, 2022 8:00 AM - PR NewsWire AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease September 19, 2022 2:00 AM - PR NewsWire AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress September 15, 2022 2:00 AM - PR NewsWire AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards" September 14, 2022 11:15 AM - PR NewsWire Morgan Stanley Reiterates Overweight Rating on Abbvie (ABBV) Following Healthcare Conference September 14, 2022 10:21 AM - StreetInsider Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories September 13, 2022 8:45 AM - PR NewsWire AbbVie (ABBV) Reports New Data from Phase 3 Trials of SKYRIZI September 12, 2022 5:23 AM - StreetInsider New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 September 10, 2022 3:20 AM - PR NewsWire AbbVie (ABBV) Declares $1.41 Quarterly Dividend; 4% Yield September 9, 2022 10:27 AM - StreetInsider AbbVie Declares Quarterly Dividend September 9, 2022 10:27 AM - PR NewsWire FDA Issues Safety Communication Related to Breast Implants September 8, 2022 1:36 PM - StreetInsider New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients September 8, 2022 4:30 AM - PR NewsWire AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022 September 8, 2022 4:00 AM - PR NewsWire Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM® September 7, 2022 8:45 AM - PR NewsWire AbbVie to Present at the Morgan Stanley Healthcare Conference September 7, 2022 8:00 AM - PR NewsWire Ironwood Pharma (IRWD) Announces Positive Phase III Trial of LINZESS in Patients 6-17 with FC September 6, 2022 7:01 AM - StreetInsider SkinMedica® Launches Firm & Tone Lotion for Body August 31, 2022 9:00 AM - PR NewsWire Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report August 30, 2022 8:00 AM - PR NewsWire AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress August 29, 2022 8:00 AM - PR NewsWire Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib) August 24, 2022 7:22 PM - PR NewsWire Abbvie (ABBV) PT Lowered to $155 at Argus August 24, 2022 7:02 AM - StreetInsider Experience the JUVÉDERM® Difference with Allergan Aesthetics August 17, 2022 8:45 AM - PR NewsWire Form 10-Q AbbVie Inc. For: Jun 30 August 4, 2022 3:59 PM - SEC Filing AbbVie (ABBV) Announces FDA Approves JUVEDERM VOLUX XC for Improvement of Jawline Definition August 3, 2022 8:45 AM - StreetInsider FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition August 3, 2022 8:45 AM - PR NewsWire Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases August 1, 2022 7:05 PM - Globe NewsWire Abbvie (ABBV) PT Lowered to $155 at Piper Sandler August 1, 2022 6:11 AM - StreetInsider Abbvie (ABBV) PT Lowered to $160 at Barclays August 1, 2022 5:19 AM - StreetInsider UPDATE: Atlantic Equities Downgrades Abbvie (ABBV) to Neutral August 1, 2022 4:43 AM - StreetInsider Abbvie (ABBV) PT Lowered to $170 at BMO Capital August 1, 2022 4:03 AM - StreetInsider Abbvie (ABBV) PT Lowered to $146 at UBS August 1, 2022 3:39 AM - StreetInsider Truist Securities Reiterates Buy Rating on Abbvie (ABBV) Despite Humira Erosion, With Focus on Skyrizi/Rinvoq July 29, 2022 3:31 PM - StreetInsider AbbVie (ABBV) Shares Fall 6% Following Revenue Miss July 29, 2022 12:04 PM - StreetInsider Form 8-K AbbVie Inc. For: Jul 29 July 29, 2022 7:50 AM - SEC Filing AbbVie to pay up to $2.37 billion to settle U.S. opioid claims July 29, 2022 7:43 AM - StreetInsider AbbVie (ABBV) Tops Q2 EPS by 3c, Maintains FY EPS Guidance July 29, 2022 7:42 AM - StreetInsider AbbVie Reports Second-Quarter 2022 Financial Results July 29, 2022 7:41 AM - PR NewsWire AbbVie (ABBV) Announces EU Approval of RINVOQ as Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis July 29, 2022 5:52 AM - StreetInsider RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis July 29, 2022 2:00 AM - PR NewsWire AbbVie (ABBV) calls more active than puts into quarter results and outlook July 28, 2022 10:58 AM - StreetInsider AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease July 27, 2022 8:45 AM - StreetInsider AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease July 27, 2022 8:45 AM - PR NewsWire AbbVie (ABBV) Announces EU Approval of RINVOQ for Treatment of Adults With Moderate to Severe Ulcerative Colitis July 26, 2022 5:58 AM - StreetInsider European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis July 26, 2022 2:00 AM - PR NewsWire AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference July 25, 2022 8:00 AM - PR NewsWire AbbVie (ABBV) and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma July 20, 2022 7:04 AM - StreetInsider AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma July 20, 2022 7:00 AM - PR NewsWire Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B- July 18, 2022 10:05 AM - BizWire Genmab (GMAB) Announces That AbbVie (ABBV) Will Submit MAA to EMA for Epcoritamab for the Treatment of R/R DLBCL July 18, 2022 10:02 AM - StreetInsider AbbVie (ABBV) Submits European Marketing Authorization Application for Atogepant July 18, 2022 5:40 AM - StreetInsider AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine July 18, 2022 2:00 AM - PR NewsWire Form 3 AbbVie Inc. For: Jun 28 Filed by: Reents Scott T July 8, 2022 1:12 PM - SEC Filing AbbVie's AL003 Rights Return to Alector (ALEC) 'No Major Suprise' - Mizuho July 8, 2022 10:33 AM - StreetInsider AbbVie to Host Second-Quarter 2022 Earnings Conference Call July 8, 2022 8:00 AM - PR NewsWire Abbvie (ABBV) PT Raised to $191 at Morgan Stanley July 8, 2022 12:31 AM - StreetInsider Senate Finance report says AbbVie shifted profit overseas to cut taxes July 7, 2022 2:02 PM - StreetInsider AbbVie (ABBV) Reports Guidance Including the Impact of Acquired IPR&D and Milestones Expense Incurred During the Second Quarter of 2022 July 6, 2022 4:23 PM - StreetInsider Form 8-K AbbVie Inc. For: Jul 06 July 6, 2022 4:19 PM - SEC Filing Full Article List